Navigation Links
Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
Date:1/4/2008

ck,

non-fatal stroke or cardiovascular death (p<0.001).

-- 52 percent reduction compared with clopidogrel in stent thrombosis

(p<0.0001).

-- 30 percent relative risk reduction compared to clopidogrel in a subset

of patients with diabetes (p<0.001) on the composite endpoint of non-

fatal heart attack, non-fatal stroke, or cardiovascular death.

Risk reductions in the primary composite endpoint with prasugrel compared to clopidogrel were seen as early as three days and continued to diverge for 15 months (the duration of the trial.)

Though the incidence of non-coronary artery bypass grafting(non-CABG) bleeding in TRITON was low in both the prasugrel and clopidogrel treatment groups, prasugrel-treated patients experienced significantly higher non-CABG major bleeding (2.2% vs. 1.7%, respectively) and higher rates of life- threatening bleeding (1.3% vs. 0.8%, respectively). Death from cardiovascular causes (2% vs. 2.2%, respectively) and all-cause death (2.8% vs. 2.9%, respectively) was comparable among prasugrel-treated patients and clopidogrel- treated patients. The overall results demonstrated that for every 1,000 patients treated with prasugrel as compared with clopidogrel, there were 22 fewer patients with heart attacks and five more non-CABG-related TIMI major bleeds.

"Given the overall results from TRITON, this submission is particularly meaningful considering that cardiovascular disease is the leading cause of death in the United States and worldwide, killing 16.7 million people each year," said John Alexander, M.D., M.P.H., global head of research and development, Daiichi Sankyo Company, Limited.

Acute heart attacks and unstable angina, called acute coronary syndrome, affect more than 840,000 Americans each year and 800,000 people in Europe.(i,ii) Utilizing current medical interventions and treatments, 300,000 people continue to experience recurrent heart attacks and 450,000 people die fro
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
2. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
3. Lilly Declares Fourth-Quarter Dividend
4. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
5. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
6. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. Cephalon Submits Supplemental New Drug Application for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Nova Scotia (PRWEB) February 27, 2015 ... stage vaccine and immunotherapy company, today announced that ... its application for Fast Track designation and Phase ... vaccines, in conjunction with the mutual co-development agreement ... previously obtained Fast Track designation for the DPX-Survivac. ...
(Date:2/27/2015)... 2015 FamilyFarms Group is pleased to ... State Line Farms, received the 2015 Tomorrow’s Top Producer ... the age of 35, who has demonstrated excellence in ... to win the Tomorrow's Top Producer Horizon Award. Every ... Top Producer Award and learning from their experiences. It ...
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital ... Factual Stock Report coverage on MabVax Therapeutics Holdings Inc ... is a clinical stage biotechnology company focused on the ... medical needs in the treatment of cancer. MabVax has ... on the protective immune responses generated by patients who ...
(Date:2/26/2015)... LEXINGTON, Mass., Feb. 26, 2015   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... and provided 2015 goals, other key objectives, and ... conference call today at 4:30 p.m. EST to ... business update.  To participate in today,s call by ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... Cato Research Ltd., a global,contract research and development organization, ... new President., Mr. Cline comes to Cato Research ... recently served as President and CEO. Mr. Cline has ... sales,and marketing roles at Organon Inc., Caremark, a division ...
... ANDS ) announced today that it will present ... Tuesday, March 18, 2008 at,3:10 p.m. EDT (12:10 p.m. ... Copley Place., Steve Worland, Ph.D., President and Chief ... of Anadys and its two,development-stage product candidates, ANA598 and ...
... March 11 Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ... Cowen and Company 28th Annual Health Care Conference ... Interested parties may access a live,webcast of the ... that listeners log on 15 minutes early in ...
Cached Biology Technology:Cato Research Names John Cline as President 2Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference 2
(Date:1/22/2015)... /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry news, ... website design. "When we launched FindBiometrics 12 years ... O,Neill , founder and CEO of FindBiometrics. "Now it,s maturing ... the key players on a very broad scale.  We are ...
(Date:1/22/2015)... , Jan. 16, 2015  A man-made form of ... and other mental capabilities in adults with mild cognitive ... study led by researchers at Wake Forest Baptist Medical ... diagnosed with amnesic mild cognitive impairment (MCI) or mild ...
(Date:1/22/2015)... 22, 2015 , Europe,s ... The European Patent Office to present a video retrospective of ... to be featured: Christofer Toumazou and Sophie Wilson ... and winners of the Award   Starting on 22 ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... the California Institute of Technology (Caltech) pioneered the ... immune system and neurodevelopmental disorders such as autism ... brains and of individuals with autism, as well ... alterations in the immune system and autism spectrum ...
... 17, 2012 Toronto Scientists have discovered two ... occurring in nearly half the patients treated with antipsychotic ... Addiction and Mental Health (CAMH). These results ... the variations, enabling clinicians to choose strategies to prevent ...
... have learnt not to use their calls at the same ... at the Polytechnic University of Catalonia have used this form ... to network nodes an operation that can be applied ... be coloured with the least possible number of colours without ...
Cached Biology News:Caltech researchers find evidence of link between immune irregularities and autism 2Caltech researchers find evidence of link between immune irregularities and autism 3Genetic link to rapid weight gain from antipsychotics discovered 2Genetic link to rapid weight gain from antipsychotics discovered 3Frog calls inspire a new algorithm for wireless networks 2
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Anti-Human alpha2-Antiplasmin Purified (Polyclonal) (goat IgG)...
Volume adapter mounts on top of the 96 well FiltrEX filter plate and allows larger volumes (1mL) to be applied to each well in a filter plate. Adapters are nonsterile....
... The Mini-PROTEAN 3 Dodeca cell with multi-casting chamber ... up to 12 mini format handcast (8.3 x ... gels. The cell requires 3.4-4.4 L of buffer ... coil that attaches to an external refrigerated circulator ...
Biology Products: